Elke Wühl

Prof. Dr. Elke Wühl

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
DDDorota Drożdż
Dorota Drożdż
Julio Alvarez PittiJulio Alvarez Pitti
Julio Alvarez Pitti
MWMałgorzata Wójcik
Małgorzata Wójcik
Claudio  BorghiClaudio Borghi
Claudio Borghi
Rosita GabbianelliRosita Gabbianelli
Rosita Gabbianelli
EWElke Wühl
Elke Wühl
Obesity has become a major epidemic in the 21st century. It increases the risk of dyslipidemia, hypertension, and type 2 diabetes, which are known cardiometabolic risk factors and components of the metabolic syndrome. Although overt cardiovascular (CV) diseases such as stroke or myocardial infarction are the domain of adulthood, it is evident that the CV continuum begins very early in life. Recognition of risk factors and early stages of CV damage, at a time when these processes are still reversible, and the development of prevention strategies are major pillars in reducing CV morbidity and mortality in the general population. In this review, we will discuss the role of well-known but also novel risk factors linking obesity and increased CV risk from prenatal age to adulthood, including the role of perinatal factors, diet, nutrigenomics, and nutri-epigenetics, hyperuricemia, dyslipidemia, hypertension, and cardiorespiratory fitness. The importance of ‘tracking’ of these risk factors on adult CV health is highlighted and the economic impact of childhood obesity as well as preventive strategies are discussed.

1 January 2013 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
EWElke Wühl
Elke Wühl
KSKarlijn J. van Stralen
Karlijn J. van Stralen
EVEnrico Eugenio Verrina
Enrico Eugenio Verrina
ABAnna Bjerre
Anna Bjerre
CWChristoph Wanner
Christoph Wanner
FSFranz Schaefer
Franz Schaefer
Summary: Background and objectives: Congenital anomalies of the kidney and urinary tract (CAKUT) are the leading cause of ESRD in children, but the proportion of patients with individual CAKUT entities progressing to ESRD during adulthood and their long-term clinical outcomes are unknown. This study assessed the age at onset of renal replacement therapy (RRT) and patient and renal graft survival in patients with CAKUT across the entire age range. Design, setting, participants, & measurements: Patients with CAKUT were compared with age-matched patients who were undergoing RRT for other renal disorders on the basis of data from the European Renal Association-European Dialysis and Transplant Association Registry. Competing risk and Cox regression analyses were conducted. Results: Of 212,930 patients commencing RRT from 1990 to 2009, 4765 (2.2%) had renal diagnoses consistent with CAKUT. The proportion of incident RRT patients with CAKUT decreased from infancy to childhood and then increased until age 15–19 years, followed by a gradual decline throughout adulthood. Median age at RRT start was 31 years in the CAKUT cohort and 61 years in the non-CAKUT cohort (P<0.001). RRT was started earlier (median, 16 years) in patients with isolated renal dysplasia than in those with renal hypoplasia and associated urinary tract disorders (median, 29.5–39.5 years). Patients with CAKUT survived longer than age- and sex-matched non-CAKUT controls because of lower cardiovascular mortality (10-year survival rate, 76.4% versus 70.7%; P<0.001). Conclusions: CAKUT leads to ESRD more often at adult than pediatric age. Treatment outcomes differ from those of acquired kidney diseases and vary within CAKUT subcategories.

24 August 2018 in Acta Paediatrica
Verified
Journal Article
Closed access
PDF file
EWElke Wühl
Elke Wühl

1 May 2008 in Pediatric Nephrology
Verified
Journal Article
Open access
PDF file
EWElke Wühl
Elke Wühl
FSFranz Schaefer
Franz Schaefer
Childhood chronic kidney disease commonly progresses toward end-stage renal failure, largely independent of the underlying disorder, once a critical impairment of renal function has occurred. Hypertension and proteinuria are the most important independent risk factors for renal disease progression. Therefore, current therapeutic strategies to prevent progression aim at controlling blood pressure and reducing urinary protein excretion. Renin-angiotensin-system (RAS) antagonists preserve kidney function not only by lowering blood pressure but also by their antiproteinuric, antifibrotic, and anti-inflammatory properties. Intensified blood pressure control, probably aiming for a target blood pressure below the 75th percentile, may exert additional renoprotective effects. Other factors contributing in a multifactorial manner to renal disease progression include dyslipidemia, anemia, and disorders of mineral metabolism. Measures to preserve renal function should therefore also comprise the maintenance of hemoglobin, serum lipid, and calcium-phosphorus ion product levels in the normal range.

1 September 2008 in Pediatric Research
Verified
Journal Article
Closed access
PDF file
GSGiacomo D Simonetti
Giacomo D Simonetti
RVRodo O von Vigier
Rodo O von Vigier
EWElke Wühl
Elke Wühl
MMMarkus G Mohaupt
Markus G Mohaupt

28 November 2014 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
IAIrene Alberici
Irene Alberici
ABAysun Karabay Bayazit
Aysun Karabay Bayazit
DDDorota Drozdz
Dorota Drozdz
SESevinç Emre
Sevinç Emre
MFMichel Fischbach
Michel Fischbach
TTThe Predict Trial
The Predict Trial